BPC-157 may not be appropriate when: Imaging or specialist review has not yet been completed for a suspected structural injury There are acute red flag features (severe weakness, fever, rapid unexplained swelling, neurological changes, unexplained weight loss) The patient has active cancer or a history of certain cancers where angiogenic peptides require careful risk assessment The goal is rapid results without addressing underlying load, rehabilitation, or lifestyle drivers A peptide should not be used to delay evaluation that is clearly warranted
Products sold online as research use only have the possibility of containing contaminants, impurities or incorrect doses
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY
Fibromyalgia and neuropathy represent chronic pain conditions where regenerative peptides may address the underlying cause rather than just masking symptoms
Disclaimer This article is for informational and educational purposes only
PCAC will discuss inclusion on the 503A Bulks List